The increased survival rate of genetically modified MSCs, generated via the co-overexpression of BCL2 + BDNF and BCLXL + BDNF, increases the likelihood of transplant survival after a stroke procedure, such as transplantation. This evidence concerns the gene BCL2 and stroke disorder.